Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mometasone Furoate vs Fluticasone Propionate in Perennial Allergic Rhinitis
NCT00783224Phase 3Completed
- Sponsor
- Organon & Co.
- Start
- Sep 2005
- Primary completion
- Nov 2005
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of mometasone furoate nasal spray in perennial allergic rhinitis (PAR) (4 arms), sponsored by Organon & Co. Primary endpoint: Change in 4 Nasal Symptom Score (Sneezing Attack, Rhinorrhea, Nasal Congestion, and Nasal Itching) at 2 weeks. Started Sep 2005; status: completed.
02
Drugs
mometasone furoate nasal spray
03
Conditions
perennial allergic rhinitis (PAR)
Beyond the preview
Go deeper on NCT00783224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00783224.